On August 27, 2021 Scandion Oncology A/S reported that the company has obtained approval from the German regulatory authorities to initiate clinical trials in Germany with SCO-101 in the PANTAX Ib study (Press release, Scandion Oncology, AUG 27, 2021, View Source,c3404242 [SID1234586967]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The German medicines agency (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) and the German ethics committee have given approval, allowing Scandion Oncology to expand the PANTAX Ib study to Germany.

"We are very pleased to receive this German approval as BfArM is highly regarded and known for having tough critera. The approval is important for the PANTAX Ib study, but it also opens the door to starting trials in Germany with SCO-101 in other indications. We will communicate more about our plans and strategy at our Capital Markets Day on September 8," said Bo Rode Hansen, President & CEO of Scandion Oncology.